Replies to post #3372 on Insmed Inc (INSM)

[Christiaan F]

TRANSCRIPT Q3-CC

"We undertake no obligation to update or revise the information provided in this call, whether as the result of new information,
future events or otherwise. Before I make the introductions, I would like to state that the patents litigation trials of Genentech
and Tercica vs. Insmed will begin in Oakland, California on Monday, November 6, in the Northern District Court of the U.S. Circuit
Court. Therefore, we will not be making any comments on this litigation.
It is now my pleasure to introduce you to the participants in today's call: Dr. Geoffrey Allan, the President and Chief Executive
Officer at Insmed; Kevin Tully, Chief Financial Officer; and Philip Young, Chief Business Officer. It's now my pleasure to turn the
call over to Dr. Geoffrey Allan for opening remarks. Geoff?
Dr. Geoffrey Allan - Insmed Incorporated - Chairman, CEO, President
Thank you, Jody. Good morning, everybody and thank you for joining the call this afternoon. Insmed has enjoyed a very
productive third quarter result as well as year-to-date for 2006. Let me briefly review some of the year's activities before passing
over to some of the management here for more detailed presentation.
Since we launched IPLEX to the pediatric endocrine market late in the second quarter, we have been gratified to witness a good
physician adoption for the growing number of children on therapy. Still, we'll update you on our progress in a moment.
We continued our label expansion studies for IPLEX and now we have ongoing clinical studies where we are evaluating the
value of IPLEX in several disease areas, such as severe insulin resistance, myotonic muscular dystrophy, AIDS [unintelligible]
dystrophy and we're about to initiate a new clinical study in children with Newman's Syndrome.
Positive data from our severe insular resistance study and our pivotal IGFD studies were presented at several [unintelligible] of
the Congress this last quarter and we hope to present top-line data from these new studies in the first half of 2007.
In the second quarter, we also submitted our European market application. THE EMEA has validated and accepted our application
and we anticipate working with this agency to gain approval in 2007. I am happy to say that we are making all of this progress
while staying within the financial guidance provided to you earlier this year and Kevin will provide more detail of our financial
performance in a moment.
So with that very brief overview, I will now pass on to Phil to present our business results. Phil?"

http://preview.tinyurl.com/y2hm6x

PY comments in more detail and is doing Q&A session with Osborne, as written in earlier post! Please read trial approved transcript!

Jody was NOT at R&R! PY was presenting! Only PY.

CF

[read_this_n0w]

Useless discission guys, it is early 2007
(which false well into the first halve of 2007)

and yes the last CC indeed mentions first halve 2007
DoDD comment was true there, so i would keep that as a timeline, since some were expected late 2006 even

"Matt Osborne - Lazard Capital Markets - Analyst
Okay, one last question and I'll jump into the queue. The timing for the next data either from severe resistant myotonic muscular dystrophy, AIDS [like] dystrophy, when can we expect to see the next data?
Phil Young - Insmed Incorporated - Chief Business Officer
We expect to see it in early '07 for everything you just mentioned."


Pfew.. seems the yahoo bashers tuned it up even during the weekends, yahoo looks awfully poluted again

glad we do not have there here

have a nice weekend people, will be a nice closing into november
=)))